INFINITY - IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity!

February 2013 | 8 pages | ID: I3942F021D6EN
MP Advisors

Abstracts

Regaining WW rights of IPI-145 (PI3K-delta, gamma isoform inhibitor, PhI/II, hematological malignancies, inflammation) from Takeda and targeting both hematologic malignancies and inflammation indication has sparked interest in Infinity Pharma (INFI). Despite limited clinical data in hand, PC and in vitro study demonstrates competitive advantages vs. drugs in pipeline hence the licensing/acquisition chances are bright. Based on PC data, IPI-145 is more potent than Gilead’s PI3K inhibitor Idelalisib (GS1101, PhIII). In a PhI study, IPI-145 has shown rapid onset of clinical activity in CLL/SLL as mono therapy. IPI-145’s Potential not dimmed even as a 3rd/4th ………. For more details, please read our report released on 13th February 2013 on INFI titled “IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity!”